John A Glaspy

Title(s)Professor, Medicine
SchoolMedicine
vCardDownload vCard

    Collapse Overview 
    Collapse Overview
    Dr. John A. Glaspy holds the Simms/Mann Family Foundation Chair in Integrative Oncology.

    Collapse Research 
    Collapse Research Activities and Funding
    CLINICAL EVALUATION OF BIOLOGICAL RESPONSE MODIFIERS
    NIH/NCI N01CM007439Sep 30, 1980
    Role: Principal Investigator

    Collapse ORNG Applications 
    Collapse Clinical Trials

    Collapse Bibliographic 
    Collapse Publications
    Publications listed below are automatically derived from MEDLINE/PubMed and other sources, which might result in incorrect or missing publications. Researchers can login to make corrections and additions, or contact us for help. to make corrections and additions.
    Newest   |   Oldest   |   Most Cited   |   Most Discussed   |   Timeline   |   Field Summary   |   Plain Text
    Altmetrics Details PMC Citations indicate the number of times the publication was cited by articles in PubMed Central, and the Altmetric score represents citations in news articles and social media. (Note that publications are often cited in additional ways that are not shown here.) Fields are based on how the National Library of Medicine (NLM) classifies the publication's journal and might not represent the specific topic of the publication. Translation tags are based on the publication type and the MeSH terms NLM assigns to the publication. Some publications (especially newer ones and publications not in PubMed) might not yet be assigned Field or Translation tags.) Click a Field or Translation tag to filter the publications.
    1. Roxadustat versus placebo for patients with lower-risk myelodysplastic syndrome: MATTERHORN phase 3, double-blind, randomized controlled trial. Am J Hematol. 2024 Jun 17. Mittelman M, Henry DH, Glaspy JA, Tombak A, Harrup R, Kim I, Madry K, Grabowska B, Lee T, Modelska K. PMID: 38884137.
      View in: PubMed   Mentions:    Fields:    
    2. Efbemalenograstim alfa not inferior to pegfilgrastim in providing neutrophil support in women with breast cancer undergoing myelotoxic chemotherapy: results of a phase 2 randomized, multicenter, open-label trial. Support Care Cancer. 2024 Jan 09; 32(2):91. Glaspy J, Bondarenko I, Krasnozhon D, Rutty D, Chen J, Fu Y, Wang S, Hou Q, Li S. PMID: 38194162; PMCID: PMC10776461.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    3. Efbemalenograstim alfa, an Fc fusion protein, long-acting granulocyte-colony stimulating factor for reducing the risk of febrile neutropenia following chemotherapy: results of a phase III trial. Support Care Cancer. 2023 Dec 16; 32(1):34. Glaspy J, Bondarenko I, Burdaeva O, Chen J, Rutty D, Li R, Wang S, Hou Q, Li S. PMID: 38103088; PMCID: PMC10725375.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCellsCTClinical Trials
    4. Development of a Novel CLDN18.2-directed Monoclonal Antibody and Antibody-Drug Conjugate for Treatment of CLDN18.2-Positive Cancers. Mol Cancer Ther. 2023 Dec 01; 22(12):1365-1375. O'Brien NA, McDermott MSJ, Zhang J, Gong KW, Lu M, Hoffstrom B, Luo T, Ayala R, Chau K, Liang M, Madrid AM, Donahue TR, Glaspy JA, Presta L, Slamon DJ. PMID: 37788341.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansAnimalsCells
    5. A Pilot Study of Neoadjuvant Nivolumab, Ipilimumab, and Intralesional Oncolytic Virotherapy for HER2-negative Breast Cancer. Cancer Res Commun. 2023 08; 3(8):1628-1637. Nguyen VP, Campbell KM, Nowicki TS, Elumalai N, Medina E, Baselga-Carretero I, DiNome ML, Chang HR, Oseguera DK, Ribas A, Glaspy JA. PMID: 37621406; PMCID: PMC10445661.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    6. Preclinical Efficacy of the Antibody-Drug Conjugate CLDN6-23-ADC for the Treatment of CLDN6-Positive Solid Tumors. Clin Cancer Res. 2023 06 01; 29(11):2131-2143. McDermott MSJ, O'Brien NA, Hoffstrom B, Gong K, Lu M, Zhang J, Luo T, Liang M, Jia W, Hong JJ, Chau K, Davenport S, Xie B, Press MF, Panayiotou R, Handly-Santana A, Brugge JS, Presta L, Glaspy J, Slamon DJ. PMID: 36884217; PMCID: PMC10233360.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCellsCTClinical Trials
    7. Talimogene laherparepvec in combination with ipilimumab versus ipilimumab alone for advanced melanoma: 5-year final analysis of a multicenter, randomized, open-label, phase II trial. J Immunother Cancer. 2023 05; 11(5). Chesney JA, Puzanov I, Collichio FA, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan T, Hauschild A, Lebbé C, Joshi H, Snyder W, Mehnert JM. PMID: 37142291; PMCID: PMC10163510.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    8. Safety and Efficacy Results From iSABR, a Phase 1 Study of Stereotactic ABlative Radiotherapy in Combination With Durvalumab for Early-Stage Medically Inoperable Non-Small Cell Lung Cancer. Int J Radiat Oncol Biol Phys. 2023 09 01; 117(1):118-122. Wu TC, Stube A, Felix C, Oseguera D, Romero T, Goldman J, Garon EB, Lee JM, Glaspy J, Lisberg AE, Rusthoven CG, Camidge DR, Siva S, Solomon B, Lee A, Tenn SE, Shaverdian N, Steinberg ML, Raldow AC, Lee P. PMID: 37023987.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    9. Open-label, Phase 2 study of roxadustat for the treatment of anemia in patients receiving chemotherapy for non-myeloid malignancies. Am J Hematol. 2023 05; 98(5):703-711. Glaspy J, Gabrail NY, Locantore-Ford P, Lee T, Modelska K, Samal V, Henry DH. PMID: 36710399.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    10. Results of TRIO-15, a multicenter, open-label, phase II study of the efficacy and safety of ganitumab in patients with recurrent platinum-sensitive ovarian cancer. Gynecol Oncol. 2023 03; 170:221-228. Davidson TM, Lebreton CL, Hendricksen AEW, Atkinson HJ, Larson MC, Oberg AL, Provencher DM, Glaspy JA, Karlan BY, Slamon DJ, Konecny GE, Ray-Coquard IL. PMID: 36709663; PMCID: PMC10425916.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    11. Preclinical and Clinical Trial Results Using Talazoparib and Low-Dose Chemotherapy. Clin Cancer Res. 2023 01 04; 29(1):40-49. Wainberg ZA, Singh AS, Konecny GE, McCann KE, Hecht JR, Goldman J, Chmielowski B, Finn RS, O'Brien N, Von Euw E, Price MM, Martinez D, Yonemoto L, Brennan M, Glaspy JA, Slamon DJ. PMID: 36136304.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    12. Risks for Anaphylaxis With Intravenous Iron Formulations. Ann Intern Med. 2022 11; 175(11):W143. Al-Samkari H, Glaspy JA, Means RT, Chertow GM, Auerbach M. PMID: 36375165.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    13. Exceptional Response to Erdafitinib in FGFR2-Mutated Metastatic Pancreatic Ductal Adenocarcinoma. J Natl Compr Canc Netw. 2022 10; 20(10):1076-1079. Ng CF, Glaspy J, Placencio-Hickok VR, Thomassian S, Gong J, Osipov A, Hendifar AE, Moshayedi N. PMID: 36240849.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    14. Chemotherapy-Induced Neutropenia and Febrile Neutropenia in the US: A Beast of Burden That Needs to Be Tamed? Oncologist. 2022 08 05; 27(8):625-636. Boccia R, Glaspy J, Crawford J, Aapro M. PMID: 35552754; PMCID: PMC9355811.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansPHPublic Health
    15. NCCN Guidelines® Insights: Hematopoietic Growth Factors, Version 1.2022. J Natl Compr Canc Netw. 2022 05; 20(5):436-442. Griffiths EA, Roy V, Alwan L, Bachiashvili K, Baird J, Cool R, Dinner S, Geyer M, Glaspy J, Gojo I, Hicks A, Kallam A, Kidwai WZ, Kloth DD, Kraut EH, Landsburg D, Lyman GH, Mahajan A, Miller R, Nachar V, Patel S, Patel S, Perez LE, Poust A, Riaz F, Rosovsky R, Rugo HS, Simon S, Vasu S, Wadleigh M, Westbrook K, Westervelt P, Berardi RA, Pluchino L. PMID: 35545171.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    16. Long-term outcomes of patients with active melanoma brain metastases treated with combination nivolumab plus ipilimumab (CheckMate 204): final results of an open-label, multicentre, phase 2 study. Lancet Oncol. 2021 12; 22(12):1692-1704. Tawbi HA, Forsyth PA, Hodi FS, Algazi AP, Hamid O, Lao CD, Moschos SJ, Atkins MB, Lewis K, Postow MA, Thomas RP, Glaspy J, Jang S, Khushalani NI, Pavlick AC, Ernstoff MS, Reardon DA, Kudchadkar R, Tarhini A, Chung C, Ritchings C, Durani P, Askelson M, Puzanov I, Margolin KA. PMID: 34774225; PMCID: PMC9328029.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    17. Roxadustat for the treatment of anemia in patients with lower-risk myelodysplastic syndrome: Open-label, dose-selection, lead-in stage of a phase 3 study. Am J Hematol. 2022 02 01; 97(2):174-184. Henry DH, Glaspy J, Harrup R, Mittelman M, Zhou A, Carraway HE, Bradley C, Saha G, Modelska K, Bartels P, Leong R, Yu KP. PMID: 34724251.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCTClinical Trials
    18. Impact of a Palliative Care Nurse Practitioner in an Oncology Clinic: A Quality Improvement Effort. JCO Oncol Pract. 2022 04; 18(4):e484-e494. D'Ambruoso SF, Glaspy JA, Hurvitz SA, Wenger NS, Pietras C, Ahmed K, Drakaki A, Goldman JW, Anand S, Simon W, Kung J, Coscarelli A, Rosen LS, Peddi PF, Wong DJL, Santos K, Phung P, Karlin D, Walling AM. PMID: 34748398.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    19. Safety and efficacy of the combination of nivolumab plus ipilimumab in patients with melanoma and asymptomatic or symptomatic brain metastases (CheckMate 204). Neuro Oncol. 2021 11 02; 23(11):1961-1973. Tawbi HA, Forsyth PA, Hodi FS, Lao CD, Moschos SJ, Hamid O, Atkins MB, Lewis K, Thomas RP, Glaspy JA, Jang S, Algazi AP, Khushalani NI, Postow MA, Pavlick AC, Ernstoff MS, Reardon DA, Puzanov I, Kudchadkar RR, Tarhini AA, Sumbul A, Rizzo JI, Margolin KA. PMID: 33880555; PMCID: PMC8563325.
      View in: PubMed   Mentions: 37     Fields:    Translation:Humans
    20. Multiplexed imaging reveals an IFN-γ-driven inflammatory state in nivolumab-associated gastritis. Cell Rep Med. 2021 10 19; 2(10):100419. Ferrian S, Liu CC, McCaffrey EF, Kumar R, Nowicki TS, Dawson DW, Baranski A, Glaspy JA, Ribas A, Bendall SC, Angelo M. PMID: 34755133; PMCID: PMC8561237.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCells
    21. Results of TRIO-14, a phase II, multicenter, randomized, placebo-controlled trial of carboplatin-paclitaxel versus carboplatin-paclitaxel-ganitumab in newly diagnosed epithelial ovarian cancer. Gynecol Oncol. 2021 12; 163(3):465-472. Konecny GE, Hendrickson AEW, Davidson TM, Winterhoff BJ, Ma S, Mahner S, Sehouli J, Fasching PA, Feisel-Schwickardi G, Poelcher M, Roman LD, Rody A, Karlan BY, Mullany SA, Chen H, Ray-Coquard IL, Provencher DM, Yachnin A, Cottu PH, Glaspy JA, Haluska P, Slamon DJ. PMID: 34642026.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    22. A careful reassessment of anthracycline use in curable breast cancer. NPJ Breast Cancer. 2021 Oct 08; 7(1):134. Hurvitz SA, McAndrew NP, Bardia A, Press MF, Pegram M, Crown JP, Fasching PA, Ejlertsen B, Yang EH, Glaspy JA, Slamon DJ. PMID: 34625570; PMCID: PMC8501074.
      View in: PubMed   Mentions: 15  
    23. Multicenter, double-blind, placebo-controlled trial of seviprotimut-L polyvalent melanoma vaccine in patients with post-resection melanoma at high risk of recurrence. J Immunother Cancer. 2021 10; 9(10). Slingluff CL, Lewis KD, Andtbacka R, Hyngstrom J, Milhem M, Markovic SN, Bowles T, Hamid O, Hernandez-Aya L, Claveau J, Jang S, Philips P, Holtan SG, Shaheen MF, Curti B, Schmidt W, Butler MO, Paramo J, Lutzky J, Padmanabhan A, Thomas S, Milton D, Pecora A, Sato T, Hsueh E, Badarinath S, Keech J, Kalmadi S, Kumar P, Weber R, Levine E, Berger A, Bar A, Beck JT, Travers JB, Mihalcioiu C, Gastman B, Beitsch P, Rapisuwon S, Glaspy J, McCarron EC, Gupta V, Behl D, Blumenstein B, Peterkin JJ. PMID: 34599031; PMCID: PMC8488725.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    24. A Randomized Phase II Study of Nivolumab Monotherapy or Nivolumab Combined with Ipilimumab in Patients with Advanced Gastrointestinal Stromal Tumors. Clin Cancer Res. 2022 01 01; 28(1):84-94. Singh AS, Hecht JR, Rosen L, Wainberg ZA, Wang X, Douek M, Hagopian A, Andes R, Sauer L, Brackert SR, Chow W, DeMatteo R, Eilber FC, Glaspy JA, Chmielowski B. PMID: 34407970.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCTClinical Trials
    25. Intravenous Iron-Induced Hypophosphatemia: An Emerging Syndrome. Adv Ther. 2021 07; 38(7):3531-3549. Glaspy JA, Wolf M, Strauss WE. PMID: 34053011; PMCID: PMC8279965.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    26. Cost-Health Literacy as an Educational Objective in Fellowship Training. J Cancer Educ. 2022 10; 37(5):1479-1485. Fischer KA, Anand S, Walling A, Larson SM, Glaspy J. PMID: 33761118.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    27. Financial Toxicity From Generic Specialty Drug Use. JAMA Oncol. 2021 02 01; 7(2):175-176. Fischer KA, Miller RE, Glaspy JA. PMID: 33211083.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    28. Epoetin alfa-epbx: a new entrant into a crowded market. a historical review of the role of erythropoietin stimulating agents and the development of the first epoetin biosimilar in the United States. Expert Rev Clin Pharmacol. 2021 Jan; 14(1):1-8. Anand S, Al-Mondhiry J, Fischer K, Glaspy J. PMID: 33307871.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    29. Safety of ferric derisomaltose and iron sucrose in patients with iron deficiency anemia: The FERWON-IDA/NEPHRO trials. Am J Hematol. 2021 01; 96(1):E11-E15. Wolf M, Auerbach M, Kalra PA, Glaspy J, Thomsen LL, Bhandari S. PMID: 33027541; PMCID: PMC7756775.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    30. Nivolumab Treatment of Burkitt Lymphoma: A Case Report. Ann Intern Med. 2021 04; 174(4):567-568. Colton BS, Hornstein N, Timmerman J, Larson S, Glaspy J. PMID: 33105097.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    31. Workup of anemia in cancer. Clin Adv Hematol Oncol. 2020 Oct; 18(10):640-646. Anand S, Burkenroad A, Glaspy J. PMID: 33201870.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    32. Gemcitabine/nab-paclitaxel with pamrevlumab: a novel drug combination and trial design for the treatment of locally advanced pancreatic cancer. ESMO Open. 2020 08; 5(4). Picozzi V, Alseidi A, Winter J, Pishvaian M, Mody K, Glaspy J, Larson T, Matrana M, Carney M, Porter S, Kouchakji E, Rocha F, Carrier E. PMID: 32817130; PMCID: PMC7440698.
      View in: PubMed   Mentions: 24  Translation:Humans
    33. A 6 month extension trial evaluating safety and efficacy of ferric derisomaltose in patients with iron deficiency anemia: The FERWON-EXT trial. Am J Hematol. 2020 Oct; 95(10):E276-E279. Achebe MM, Glaspy J, Kalra PA, Auerbach M, Thomsen LL, Bhandari S. PMID: 32602177; PMCID: PMC7539947.
      View in: PubMed   Mentions: 3     Fields:    
    34. Hypophosphatemia Associated with Intravenous Iron Therapies for Iron Deficiency Anemia: A Systematic Literature Review. Ther Clin Risk Manag. 2020; 16:245-259. Glaspy JA, Lim-Watson MZ, Libre MA, Karkare SS, Hadker N, Bajic-Lucas A, Strauss WE, Dahl NV. PMID: 32308402; PMCID: PMC7152545.
      View in: PubMed   Mentions: 23  
    35. Cost health literacy as a physician skill-set: the relationship between oncologist reported knowledge and engagement with patients on financial toxicity. Support Care Cancer. 2020 Dec; 28(12):5709-5715. Fischer KA, Walling A, Wenger N, Glaspy J. PMID: 32193693.
      View in: PubMed   Mentions: 8     Fields:    Translation:Humans
    36. Establishing a Denominator for Palliative Care Quality Metrics for Patients with Advanced Cancer. J Palliat Med. 2020 09; 23(9):1239-1242. Anand S, Glaspy J, Roh L, Khandelwal V, Wenger N, Ritchie C, Walling AM. PMID: 31928372.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    37. Adjuvant denosumab in early breast cancer (D-CARE): an international, multicentre, randomised, controlled, phase 3 trial. Lancet Oncol. 2020 01; 21(1):60-72. Coleman R, Finkelstein DM, Barrios C, Martin M, Iwata H, Hegg R, Glaspy J, Periañez AM, Tonkin K, Deleu I, Sohn J, Crown J, Delaloge S, Dai T, Zhou Y, Jandial D, Chan A. PMID: 31806543.
      View in: PubMed   Mentions: 81     Fields:    Translation:HumansCTClinical Trials
    38. A prospective, multi-center, randomized comparison of iron isomaltoside 1000 versus iron sucrose in patients with iron deficiency anemia; the FERWON-IDA trial. Am J Hematol. 2019 09; 94(9):1007-1014. Auerbach M, Henry D, Derman RJ, Achebe MM, Thomsen LL, Glaspy J. PMID: 31243803; PMCID: PMC6772897.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    39. Focal Irradiation and Systemic TGFβ Blockade in Metastatic Breast Cancer. Clin Cancer Res. 2018 06 01; 24(11):2493-2504. Formenti SC, Lee P, Adams S, Goldberg JD, Li X, Xie MW, Ratikan JA, Felix C, Hwang L, Faull KF, Sayre JW, Hurvitz S, Glaspy JA, Comin-Anduix B, Demaria S, Schaue D, McBride WH. PMID: 29476019; PMCID: PMC5999326.
      View in: PubMed   Mentions: 122     Fields:    Translation:HumansCTClinical Trials
    40. Randomized, Open-Label Phase II Study Evaluating the Efficacy and Safety of Talimogene Laherparepvec in Combination With Ipilimumab Versus Ipilimumab Alone in Patients With Advanced, Unresectable Melanoma. J Clin Oncol. 2018 06 10; 36(17):1658-1667. Chesney J, Puzanov I, Collichio F, Singh P, Milhem MM, Glaspy J, Hamid O, Ross M, Friedlander P, Garbe C, Logan TF, Hauschild A, Lebbé C, Chen L, Kim JJ, Gansert J, Andtbacka RHI, Kaufman HL. PMID: 28981385; PMCID: PMC6075852.
      View in: PubMed   Mentions: 298     Fields:    Translation:HumansCellsCTClinical Trials
    41. Refining the role of pegfilgrastim (a long-acting G-CSF) for prevention of chemotherapy-induced febrile neutropenia: consensus guidance recommendations. Support Care Cancer. 2017 11; 25(11):3295-3304. Aapro M, Boccia R, Leonard R, Camps C, Campone M, Choquet S, Danova M, Glaspy J, Hus I, Link H, Sliwa T, Tesch H, Valero V. PMID: 28842778; PMCID: PMC5610660.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    42. Prevention of everolimus-related stomatitis in women with hormone receptor-positive, HER2-negative metastatic breast cancer using dexamethasone mouthwash (SWISH): a single-arm, phase 2 trial. Lancet Oncol. 2017 05; 18(5):654-662. Rugo HS, Seneviratne L, Beck JT, Glaspy JA, Peguero JA, Pluard TJ, Dhillon N, Hwang LC, Nangia C, Mayer IA, Meiller TF, Chambers MS, Sweetman RW, Sabo JR, Litton JK. PMID: 28314691.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCTClinical Trials
    43. Phase I, Dose-Escalation, Two-Part Trial of the PARP Inhibitor Talazoparib in Patients with Advanced Germline BRCA1/2 Mutations and Selected Sporadic Cancers. Cancer Discov. 2017 06; 7(6):620-629. de Bono J, Ramanathan RK, Mina L, Chugh R, Glaspy J, Rafii S, Kaye S, Sachdev J, Heymach J, Smith DC, Henshaw JW, Herriott A, Patterson M, Curtin NJ, Byers LA, Wainberg ZA. PMID: 28242752; PMCID: PMC5905335.
      View in: PubMed   Mentions: 199     Fields:    Translation:HumansCellsCTClinical Trials
    44. Oral mucosal injury caused by mammalian target of rapamycin inhibitors: emerging perspectives on pathobiology and impact on clinical practice. Cancer Med. 2016 08; 5(8):1897-907. Peterson DE, O'Shaughnessy JA, Rugo HS, Elad S, Schubert MM, Viet CT, Campbell-Baird C, Hronek J, Seery V, Divers J, Glaspy J, Schmidt BL, Meiller TF. PMID: 27334013; PMCID: PMC4971919.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    45. A Randomized Noninferiority Trial of Intravenous Iron Isomaltoside versus Oral Iron Sulfate in Patients with Nonmyeloid Malignancies and Anemia Receiving Chemotherapy: The PROFOUND Trial. Pharmacotherapy. 2016 Apr; 36(4):402-14. Birgegård G, Henry D, Glaspy J, Chopra R, Thomsen LL, Auerbach M. PMID: 26927900; PMCID: PMC5071650.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCTClinical Trials
    46. Systemic versus local responses in melanoma patients treated with talimogene laherparepvec from a multi-institutional phase II study. J Immunother Cancer. 2016; 4:12. Kaufman HL, Amatruda T, Reid T, Gonzalez R, Glaspy J, Whitman E, Harrington K, Nemunaitis J, Zloza A, Wolf M, Senzer NN. PMID: 26981242; PMCID: PMC4791835.
      View in: PubMed   Mentions: 44     Fields:    
    47. PD-1 Blockade Expands Intratumoral Memory T Cells. Cancer Immunol Res. 2016 Mar; 4(3):194-203. Ribas A, Shin DS, Zaretsky J, Frederiksen J, Cornish A, Avramis E, Seja E, Kivork C, Siebert J, Kaplan-Lefko P, Wang X, Chmielowski B, Glaspy JA, Tumeh PC, Chodon T, Pe'er D, Comin-Anduix B. PMID: 26787823; PMCID: PMC4775381.
      View in: PubMed   Mentions: 194     Fields:    Translation:HumansCellsCTClinical Trials
    48. Sotatercept (ACE-011) for the treatment of chemotherapy-induced anemia in patients with metastatic breast cancer or advanced or metastatic solid tumors treated with platinum-based chemotherapeutic regimens: results from two phase 2 studies. Support Care Cancer. 2016 Apr; 24(4):1517-25. Raftopoulos H, Laadem A, Hesketh PJ, Goldschmidt J, Gabrail N, Osborne C, Ali M, Sherman ML, Wang D, Glaspy JA, Puccio-Pick M, Zou J, Crawford J. PMID: 26370220; PMCID: PMC4766217.
      View in: PubMed   Mentions: 25     Fields:    Translation:HumansCTClinical Trials
    49. Long term survival with cytotoxic T lymphocyte-associated antigen 4 blockade using tremelimumab. Eur J Cancer. 2015 Nov; 51(17):2689-97. Eroglu Z, Kim DW, Wang X, Camacho LH, Chmielowski B, Seja E, Villanueva A, Ruchalski K, Glaspy JA, Kim KB, Hwu WJ, Ribas A. PMID: 26364516; PMCID: PMC4821004.
      View in: PubMed   Mentions: 40     Fields:    Translation:Humans
    50. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014 Nov 27; 515(7528):568-71. Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, West AN, Carmona M, Kivork C, Seja E, Cherry G, Gutierrez AJ, Grogan TR, Mateus C, Tomasic G, Glaspy JA, Emerson RO, Robins H, Pierce RH, Elashoff DA, Robert C, Ribas A. PMID: 25428505; PMCID: PMC4246418.
      View in: PubMed   Mentions: 3154     Fields:    Translation:HumansCellsCTClinical Trials
    51. Iron deficiency anemia--bridging the knowledge and practice gap. Transfus Med Rev. 2014 Jul; 28(3):156-66. Shander A, Goodnough LT, Javidroozi M, Auerbach M, Carson J, Ershler WB, Ghiglione M, Glaspy J, Lew I. PMID: 24931617.
      View in: PubMed   Mentions: 30     Fields:    Translation:Humans
    52. Current status of use of erythropoietic agents in cancer patients. Semin Thromb Hemost. 2014 Apr; 40(3):306-12. Glaspy J. PMID: 24676903.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    53. Adoptive transfer of MART-1 T-cell receptor transgenic lymphocytes and dendritic cell vaccination in patients with metastatic melanoma. Clin Cancer Res. 2014 May 01; 20(9):2457-65. Chodon T, Comin-Anduix B, Chmielowski B, Koya RC, Wu Z, Auerbach M, Ng C, Avramis E, Seja E, Villanueva A, McCannel TA, Ishiyama A, Czernin J, Radu CG, Wang X, Gjertson DW, Cochran AJ, Cornetta K, Wong DJ, Kaplan-Lefko P, Hamid O, Samlowski W, Cohen PA, Daniels GA, Mukherji B, Yang L, Zack JA, Kohn DB, Heath JR, Glaspy JA, Witte ON, Baltimore D, Economou JS, Ribas A. PMID: 24634374; PMCID: PMC4070853.
      View in: PubMed   Mentions: 112     Fields:    Translation:HumansCellsPHPublic HealthCTClinical Trials
    54. The effects of a high-fat meal on single-dose vemurafenib pharmacokinetics. J Clin Pharmacol. 2014 Apr; 54(4):368-74. Ribas A, Zhang W, Chang I, Shirai K, Ernstoff MS, Daud A, Cowey CL, Daniels G, Seja E, O'Laco E, Glaspy JA, Chmielowski B, Hill T, Joe AK, Grippo JF. PMID: 24374975.
      View in: PubMed   Mentions: 12     Fields:    Translation:Humans
    55. Acquired resistance and clonal evolution in melanoma during BRAF inhibitor therapy. Cancer Discov. 2014 Jan; 4(1):80-93. Shi H, Hugo W, Kong X, Hong A, Koya RC, Moriceau G, Chodon T, Guo R, Johnson DB, Dahlman KB, Kelley MC, Kefford RF, Chmielowski B, Glaspy JA, Sosman JA, van Baren N, Long GV, Ribas A, Lo RS. PMID: 24265155; PMCID: PMC3936420.
      View in: PubMed   Mentions: 494     Fields:    Translation:HumansCells
    56. High-dose vincristine sulfate liposome injection (Marqibo) Is not associated with clinically meaningful hematologic toxicity. Clin Lymphoma Myeloma Leuk. 2014 Jun; 14(3):197-202. Deitcher OR, Glaspy J, Gonzalez R, Sato T, Bedikian AY, Segarini K, Silverman J, Deitcher SR. PMID: 24417913.
      View in: PubMed   Mentions: 10     Fields:    Translation:Humans
    57. Health-related quality of life with adjuvant docetaxel- and trastuzumab-based regimens in patients with node-positive and high-risk node-negative, HER2-positive early breast cancer: results from the BCIRG 006 Study. Oncologist. 2013; 18(7):812-8. Au HJ, Eiermann W, Robert NJ, Pienkowski T, Crown J, Martin M, Pawlicki M, Chan A, Mackey J, Glaspy J, Pintér T, Liu MC, Fornander T, Sehdev S, Ferrero JM, Bée V, Santana MJ, Miller DP, Lalla D, Slamon DJ, Translational Research in Oncology BCIRG 006 Trial Investigators. PMID: 23814044; PMCID: PMC3720634.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    58. BRAF V600E inhibition in anaplastic thyroid cancer. N Engl J Med. 2013 Feb 14; 368(7):684-5. Rosove MH, Peddi PF, Glaspy JA. PMID: 23406047.
      View in: PubMed   Mentions: 88     Fields:    Translation:Humans
    59. Chemotherapy-induced anemia: the story of darbepoetin alfa. Curr Med Res Opin. 2013 Apr; 29(4):325-37. Vansteenkiste J, Wauters I, Elliott S, Glaspy J, Hedenus M. PMID: 23323876.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    60. Adjuvant docetaxel, doxorubicin, and cyclophosphamide in node-positive breast cancer: 10-year follow-up of the phase 3 randomised BCIRG 001 trial. Lancet Oncol. 2013 Jan; 14(1):72-80. Mackey JR, Martin M, Pienkowski T, Rolski J, Guastalla JP, Sami A, Glaspy J, Juhos E, Wardley A, Fornander T, Hainsworth J, Coleman R, Modiano MR, Vinholes J, Pinter T, Rodríguez-Lescure A, Colwell B, Whitlock P, Provencher L, Laing K, Walde D, Price C, Hugh JC, Childs BH, Bassi K, Lindsay MA, Wilson V, Rupin M, Houé V, Vogel C, TRIO/BCIRG 001 investigators. PMID: 23246022.
      View in: PubMed   Mentions: 99     Fields:    Translation:HumansCTClinical Trials
    61. Safety profile and pharmacokinetic analyses of the anti-CTLA4 antibody tremelimumab administered as a one hour infusion. J Transl Med. 2012 Nov 21; 10:236. Ribas A, Chesney JA, Gordon MS, Abernethy AP, Logan TF, Lawson DH, Chmielowksi B, Glaspy JA, Lewis K, Huang B, Wang E, Hsyu PH, Gomez-Navarro J, Gerhardt D, Marshall MA, Gonzalez R. PMID: 23171508; PMCID: PMC3543342.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCTClinical Trials
    62. BRAF(L597) mutations in melanoma are associated with sensitivity to MEK inhibitors. Cancer Discov. 2012 Sep; 2(9):791-7. Dahlman KB, Xia J, Hutchinson K, Ng C, Hucks D, Jia P, Atefi M, Su Z, Branch S, Lyle PL, Hicks DJ, Bozon V, Glaspy JA, Rosen N, Solit DB, Netterville JL, Vnencak-Jones CL, Sosman JA, Ribas A, Zhao Z, Pao W. PMID: 22798288; PMCID: PMC3449158.
      View in: PubMed   Mentions: 111     Fields:    Translation:HumansCells
    63. Update on safety of ESAs in cancer-induced anemia. J Natl Compr Canc Netw. 2012 May; 10(5):659-66. Glaspy J. PMID: 22570294.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    64. Benefits and risks of using erythropoiesis-stimulating agents (ESAs) in lung cancer patients: study-level and patient-level meta-analyses. Lung Cancer. 2012 Jun; 76(3):478-85. Vansteenkiste J, Glaspy J, Henry D, Ludwig H, Pirker R, Tomita D, Collins H, Crawford J. PMID: 22277104.
      View in: PubMed   Mentions: 15     Fields:    Translation:Humans
    65. Reversing melanoma cross-resistance to BRAF and MEK inhibitors by co-targeting the AKT/mTOR pathway. PLoS One. 2011; 6(12):e28973. Atefi M, von Euw E, Attar N, Ng C, Chu C, Guo D, Nazarian R, Chmielowski B, Glaspy JA, Comin-Anduix B, Mischel PS, Lo RS, Ribas A. PMID: 22194965; PMCID: PMC3237573.
      View in: PubMed   Mentions: 123     Fields:    Translation:HumansCells
    66. Adjuvant trastuzumab in HER2-positive breast cancer. N Engl J Med. 2011 Oct 06; 365(14):1273-83. Slamon D, Eiermann W, Robert N, Pienkowski T, Martin M, Press M, Mackey J, Glaspy J, Chan A, Pawlicki M, Pinter T, Valero V, Liu MC, Sauter G, von Minckwitz G, Visco F, Bee V, Buyse M, Bendahmane B, Tabah-Fisch I, Lindsay MA, Riva A, Crown J, Breast Cancer International Research Group. PMID: 21991949; PMCID: PMC3268553.
      View in: PubMed   Mentions: 1029     Fields:    Translation:Humans
    67. Combination therapy with vemurafenib (PLX4032/RG7204) and metformin in melanoma cell lines with distinct driver mutations. J Transl Med. 2011 May 24; 9:76. Niehr F, von Euw E, Attar N, Guo D, Matsunaga D, Sazegar H, Ng C, Glaspy JA, Recio JA, Lo RS, Mischel PS, Comin-Anduix B, Ribas A. PMID: 21609436; PMCID: PMC3152784.
      View in: PubMed   Mentions: 45     Fields:    Translation:HumansCells
    68. Phase III multicenter clinical trial of the sialyl-TN (STn)-keyhole limpet hemocyanin (KLH) vaccine for metastatic breast cancer. Oncologist. 2011; 16(8):1092-100. Miles D, Roché H, Martin M, Perren TJ, Cameron DA, Glaspy J, Dodwell D, Parker J, Mayordomo J, Tres A, Murray JL, Ibrahim NK, Theratope® Study Group. PMID: 21572124; PMCID: PMC3228158.
      View in: PubMed   Mentions: 116     Fields:    Translation:HumansCTClinical Trials
    69. CTLA4 blockade induces frequent tumor infiltration by activated lymphocytes regardless of clinical responses in humans. Clin Cancer Res. 2011 Jun 15; 17(12):4101-9. Huang RR, Jalil J, Economou JS, Chmielowski B, Koya RC, Mok S, Sazegar H, Seja E, Villanueva A, Gomez-Navarro J, Glaspy JA, Cochran AJ, Ribas A. PMID: 21558401; PMCID: PMC3117971.
      View in: PubMed   Mentions: 83     Fields:    Translation:HumansCellsCTClinical Trials
    70. Darbepoetin alfa controversies, from dosage issues to safety concerns: the larger lesson. Oncology (Williston Park). 2011 Apr 30; 25(5):423-4. Glaspy JA. PMID: 21710839.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    71. RIBBON-1: randomized, double-blind, placebo-controlled, phase III trial of chemotherapy with or without bevacizumab for first-line treatment of human epidermal growth factor receptor 2-negative, locally recurrent or metastatic breast cancer. J Clin Oncol. 2011 Apr 01; 29(10):1252-60. Robert NJ, Diéras V, Glaspy J, Brufsky AM, Bondarenko I, Lipatov ON, Perez EA, Yardley DA, Chan SY, Zhou X, Phan SC, O'Shaughnessy J. PMID: 21383283.
      View in: PubMed   Mentions: 414     Fields:    Translation:HumansCTClinical Trials
    72. Randomized controlled trials of the erythroid-stimulating agents in cancer patients. Cancer Treat Res. 2011; 157:195-215. Glaspy JA. PMID: 21052958.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    73. Multicenter phase II study of matured dendritic cells pulsed with melanoma cell line lysates in patients with advanced melanoma. J Transl Med. 2010 Sep 27; 8:89. Ribas A, Camacho LH, Lee SM, Hersh EM, Brown CK, Richards JM, Rodriguez MJ, Prieto VG, Glaspy JA, Oseguera DK, Hernandez J, Villanueva A, Chmielowski B, Mitsky P, Bercovici N, Wasserman E, Landais D, Ross MI. PMID: 20875102; PMCID: PMC2954849.
      View in: PubMed   Mentions: 13     Fields:    Translation:HumansCellsCTClinical Trials
    74. Differential response of triple-negative breast cancer to a docetaxel and carboplatin-based neoadjuvant treatment. Cancer. 2010 Sep 15; 116(18):4227-37. Chang HR, Glaspy J, Allison MA, Kass FC, Elashoff R, Chung DU, Gornbein J. PMID: 20549829.
      View in: PubMed   Mentions: 43     Fields:    Translation:Humans
    75. A phase II trial of docetaxel with bevacizumab as first-line therapy for HER2-negative metastatic breast cancer (TORI B01). Clin Breast Cancer. 2010 Aug 01; 10(4):307-12. Hurvitz SA, Allen HJ, Moroose RL, Chan D, Hagenstad C, Applebaum SH, Patel G, Hu EH, Ryba N, Lin LS, Wang H, Glaspy J, Slamon DJ, Kabbinavar F. PMID: 20705564.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCTClinical Trials
    76. Pharmacodynamic characterization of the efficacy signals due to selective BRAF inhibition with PLX4032 in malignant melanoma. Neoplasia. 2010 Aug; 12(8):637-49. Tap WD, Gong KW, Dering J, Tseng Y, Ginther C, Pauletti G, Glaspy JA, Essner R, Bollag G, Hirth P, Zhang C, Slamon DJ. PMID: 20689758; PMCID: PMC2915408.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansCells
    77. Bevacizumab and osteonecrosis of the jaw: incidence and association with bisphosphonate therapy in three large prospective trials in advanced breast cancer. Breast Cancer Res Treat. 2010 Jul; 122(1):181-8. Guarneri V, Miles D, Robert N, Diéras V, Glaspy J, Smith I, Thomssen C, Biganzoli L, Taran T, Conte P. PMID: 20361252.
      View in: PubMed   Mentions: 91     Fields:    Translation:Humans
    78. Erythropoiesis-stimulating agents in oncology: a study-level meta-analysis of survival and other safety outcomes. Br J Cancer. 2010 Jan 19; 102(2):301-15. Glaspy J, Crawford J, Vansteenkiste J, Henry D, Rao S, Bowers P, Berlin JA, Tomita D, Bridges K, Ludwig H. PMID: 20051958; PMCID: PMC2816662.
      View in: PubMed   Mentions: 54     Fields:    Translation:Humans
    79. Results of a multicenter, randomized, double-blind phase 2/3 study of lenalidomide in the treatment of pretreated relapsed or refractory metastatic malignant melanoma. Cancer. 2010 Jan 01; 116(1):146-54. Eisen T, Trefzer U, Hamilton A, Hersey P, Millward M, Knight RD, Jungnelius JU, Glaspy J. PMID: 19862820.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCTClinical Trials
    80. Do we need a different set of response assessment criteria for tumor immunotherapy? Clin Cancer Res. 2009 Dec 01; 15(23):7116-8. Ribas A, Chmielowski B, Glaspy JA. PMID: 19934296.
      View in: PubMed   Mentions: 46     Fields:    Translation:Humans
    81. Results of a multicenter, randomized, double-blind, dose-evaluating phase 2/3 study of lenalidomide in the treatment of metastatic malignant melanoma. Cancer. 2009 Nov 15; 115(22):5228-36. Glaspy J, Atkins MB, Richards JM, Agarwala SS, O'Day S, Knight RD, Jungnelius JU, Bedikian AY. PMID: 19728370.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansCTClinical Trials
    82. Phase II clinical trial of a granulocyte-macrophage colony-stimulating factor-encoding, second-generation oncolytic herpesvirus in patients with unresectable metastatic melanoma. J Clin Oncol. 2009 Dec 01; 27(34):5763-71. Senzer NN, Kaufman HL, Amatruda T, Nemunaitis M, Reid T, Daniels G, Gonzalez R, Glaspy J, Whitman E, Harrington K, Goldsweig H, Marshall T, Love C, Coffin R, Nemunaitis JJ. PMID: 19884534.
      View in: PubMed   Mentions: 275     Fields:    Translation:HumansCellsCTClinical Trials
    83. Dendritic cell vaccination combined with CTLA4 blockade in patients with metastatic melanoma. Clin Cancer Res. 2009 Oct 01; 15(19):6267-76. Ribas A, Comin-Anduix B, Chmielowski B, Jalil J, de la Rocha P, McCannel TA, Ochoa MT, Seja E, Villanueva A, Oseguera DK, Straatsma BR, Cochran AJ, Glaspy JA, Hui L, Marincola FM, Wang E, Economou JS, Gomez-Navarro J. PMID: 19789309; PMCID: PMC2765061.
      View in: PubMed   Mentions: 94     Fields:    Translation:HumansCellsCTClinical Trials
    84. Hematology: ESAs to treat anemia--balancing the risks and benefits. Nat Rev Clin Oncol. 2009 Sep; 6(9):500-2. Glaspy J. PMID: 19707239.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    85. Patterns of care in community-based oncology practices for anemia associated with myelosuppressive chemotherapy. J Oncol Pract. 2009 Sep; 5(5):236-43. Naeim A, Friedman L, Whitlock KB, Pasta DJ, Elkin EP, Lubeck DP, Viswanathan HN, Glaspy J. PMID: 20856735; PMCID: PMC2790673.
      View in: PubMed   Mentions: 1     Fields:    
    86. Interferon alfa in the postsurgical management of high-risk melanoma: is it worth it? J Clin Oncol. 2009 Jun 20; 27(18):2896-7. Glaspy J, Ribas A, Chmielowski B. PMID: 19433677.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    87. Pooled analysis of individual patient-level data from all randomized, double-blind, placebo-controlled trials of darbepoetin alfa in the treatment of patients with chemotherapy-induced anemia. J Clin Oncol. 2009 Jun 10; 27(17):2838-47. Ludwig H, Crawford J, Osterborg A, Vansteenkiste J, Henry DH, Fleishman A, Bridges K, Glaspy JA. PMID: 19380447.
      View in: PubMed   Mentions: 28     Fields:    Translation:Humans
    88. Initiation of epoetin-alpha therapy at a starting dose of 120,000 units once every 3 weeks in patients with cancer receiving chemotherapy: an open-label, multicenter study with randomized and nonrandomized treatment arms. Cancer. 2009 Mar 01; 115(5):1121-31. Glaspy JA, Charu V, Luo D, Moyo V, Kamin M, Wilhelm FE. PMID: 19170225.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    89. Intratumoral immune cell infiltrates, FoxP3, and indoleamine 2,3-dioxygenase in patients with melanoma undergoing CTLA4 blockade. Clin Cancer Res. 2009 Jan 01; 15(1):390-9. Ribas A, Comin-Anduix B, Economou JS, Donahue TR, de la Rocha P, Morris LF, Jalil J, Dissette VB, Shintaku IP, Glaspy JA, Gomez-Navarro J, Cochran AJ. PMID: 19118070.
      View in: PubMed   Mentions: 61     Fields:    Translation:HumansCells
    90. Erythropoietin in cancer patients. Annu Rev Med. 2009; 60:181-92. Glaspy JA. PMID: 18980468.
      View in: PubMed   Mentions: 23     Fields:    Translation:Humans
    91. Erythropoiesis-stimulating agents in oncology. J Natl Compr Canc Netw. 2008 Jul; 6(6):565-75. Glaspy JA. PMID: 18597710.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    92. Erythropoietins should be used according to guidelines. Lancet Oncol. 2008 May; 9(5):412-3. Aapro MS, Birgegård G, Bokemeyer C, Cornes P, Foubert J, Gascon P, Glaspy J, Hellström-Lindberg E, Link H, Ludwig H, Osterborg A, Repetto L, Soubeyran P. PMID: 18452853.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    93. Detailed analysis of immunologic effects of the cytotoxic T lymphocyte-associated antigen 4-blocking monoclonal antibody tremelimumab in peripheral blood of patients with melanoma. J Transl Med. 2008 May 01; 6:22. Comin-Anduix B, Lee Y, Jalil J, Algazi A, de la Rocha P, Camacho LH, Bozon VA, Bulanhagui CA, Seja E, Villanueva A, Straatsma BR, Gualberto A, Economou JS, Glaspy JA, Gomez-Navarro J, Ribas A. PMID: 18452610; PMCID: PMC2412852.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsCTClinical Trials
    94. Adenovirus MART-1-engineered autologous dendritic cell vaccine for metastatic melanoma. J Immunother. 2008 Apr; 31(3):294-309. Butterfield LH, Comin-Anduix B, Vujanovic L, Lee Y, Dissette VB, Yang JQ, Vu HT, Seja E, Oseguera DK, Potter DM, Glaspy JA, Economou JS, Ribas A. PMID: 18317358; PMCID: PMC3651040.
      View in: PubMed   Mentions: 47     Fields:    Translation:HumansCellsCTClinical Trials
    95. High-molecular weight iron dextran: a wolf in sheep's clothing? J Am Soc Nephrol. 2008 May; 19(5):833-4. Rodgers GM, Auerbach M, Cella D, Chertow GM, Coyne DW, Glaspy JA, Henry DH. PMID: 18369084.
      View in: PubMed   Mentions: 19     Fields:    Translation:Humans
    96. Darbepoetin alpha for the treatment of anemia in patients with active cancer not receiving chemotherapy or radiotherapy: results of a phase III, multicenter, randomized, double-blind, placebo-controlled study. J Clin Oncol. 2008 Mar 01; 26(7):1040-50. Smith RE, Aapro MS, Ludwig H, Pintér T, Smakal M, Ciuleanu TE, Chen L, Lillie T, Glaspy JA. PMID: 18227526.
      View in: PubMed   Mentions: 62     Fields:    Translation:HumansCTClinical Trials
    97. Budget impact analysis of darbepoetin alfa every 3 weeks versus epoetin alfa every week for the treatment of chemotherapy-induced anaemia from a US payer's perspective. J Med Econ. 2008; 11(2):199-213. Rubin RJ, Glaspy JA, Adams JL, Mafilios MS, Wang SM, Viswanathan HN, Kallich JD. PMID: 19450080.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    98. A randomized, open-label, multicenter trial of immediate versus delayed intervention with darbepoetin alfa for chemotherapy-induced anemia. Oncologist. 2007 Oct; 12(10):1253-63. Charu V, Saidman B, Ben-Jacob A, Justice GR, Maniam AS, Tomita D, Rossi G, Rearden T, Glaspy J. PMID: 17962619.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    99. Clinical update: intravenous iron for anaemia. Lancet. 2007 May 05; 369(9572):1502-1504. Auerbach M, Ballard H, Glaspy J. PMID: 17482969.
      View in: PubMed   Mentions: 49     Fields:    Translation:Humans
    100. Surveillance of the eye and vision in clinical trials of CP-675,206 for metastatic melanoma. Am J Ophthalmol. 2007 Jun; 143(6):958-969. Straatsma BR, Nusinowitz S, Young TA, Gordon LK, Chun MW, Rosen C, Seja E, Economou JS, Glaspy JA, Bozon V, Gomez-Navarro J, Ribas A. PMID: 17434437.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    101. Phase II study of two dose schedules of C.E.R.A. (Continuous Erythropoietin Receptor Activator) in anemic patients with advanced non-small cell lung cancer (NSCLC) receiving chemotherapy. Trials. 2007 Mar 06; 8:8. Hirsh V, Glaspy J, Mainwaring P, Manegold C, Ramlau R, Eid JE. PMID: 17341293; PMCID: PMC1831793.
      View in: PubMed   Mentions: 5     Fields:    
    102. Effect of altering dietary omega-6/omega-3 fatty acid ratios on prostate cancer membrane composition, cyclooxygenase-2, and prostaglandin E2. Clin Cancer Res. 2006 Aug 01; 12(15):4662-70. Kobayashi N, Barnard RJ, Henning SM, Elashoff D, Reddy ST, Cohen P, Leung P, Hong-Gonzalez J, Freedland SJ, Said J, Gui D, Seeram NP, Popoviciu LM, Bagga D, Heber D, Glaspy JA, Aronson WJ. PMID: 16899616; PMCID: PMC3410648.
      View in: PubMed   Mentions: 72     Fields:    Translation:HumansAnimalsCells
    103. Optimizing the dose and schedule of darbepoetin alfa in patients with chemotherapy-induced anemia. Oncology (Williston Park). 2006 Jul; 20(8 Suppl 6):29-32. Glaspy J. PMID: 16925109.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    104. Randomized comparison of every-2-week darbepoetin alfa and weekly epoetin alfa for the treatment of chemotherapy-induced anemia: the 20030125 Study Group Trial. J Clin Oncol. 2006 May 20; 24(15):2290-7. 20030125 Study Group Trial, Glaspy J, Vadhan-Raj S, Patel R, Bosserman L, Hu E, Lloyd RE, Boccia RV, Tomita D, Rossi G. PMID: 16710026.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCTClinical Trials
    105. A phase I/II trial testing immunization of hepatocellular carcinoma patients with dendritic cells pulsed with four alpha-fetoprotein peptides. Clin Cancer Res. 2006 May 01; 12(9):2817-25. Butterfield LH, Ribas A, Dissette VB, Lee Y, Yang JQ, De la Rocha P, Duran SD, Hernandez J, Seja E, Potter DM, McBride WH, Finn R, Glaspy JA, Economou JS. PMID: 16675576.
      View in: PubMed   Mentions: 95     Fields:    Translation:HumansCellsCTClinical Trials
    106. Immunosensitization of tumor cells to dendritic cell-activated immune responses with the proteasome inhibitor bortezomib (PS-341, Velcade). J Immunol. 2006 Apr 15; 176(8):4757-65. Schumacher LY, Vo DD, Garban HJ, Comin-Anduix B, Owens SK, Dissette VB, Glaspy JA, McBride WH, Bonavida B, Economou JS, Ribas A. PMID: 16585569.
      View in: PubMed   Mentions: 22     Fields:    Translation:AnimalsCellsPHPublic Health
    107. Are there clinical benefits with early erythropoietic intervention for chemotherapy-induced anemia? A systematic review. Cancer. 2006 Jan 01; 106(1):223-33. Lyman GH, Glaspy J. PMID: 16331597.
      View in: PubMed   Mentions: 5     Fields:    Translation:Humans
    108. Definition of an immunologic response using the major histocompatibility complex tetramer and enzyme-linked immunospot assays. Clin Cancer Res. 2006 Jan 01; 12(1):107-16. Comin-Anduix B, Gualberto A, Glaspy JA, Seja E, Ontiveros M, Reardon DL, Renteria R, Englahner B, Economou JS, Gomez-Navarro J, Ribas A. PMID: 16397031.
      View in: PubMed   Mentions: 17     Fields:    Translation:HumansCells
    109. Cancer patient survival and erythropoietin. J Natl Compr Canc Netw. 2005 Nov; 3(6):796-804. Glaspy JA. PMID: 16316615.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimals
    110. Antitumor activity in melanoma and anti-self responses in a phase I trial with the anti-cytotoxic T lymphocyte-associated antigen 4 monoclonal antibody CP-675,206. J Clin Oncol. 2005 Dec 10; 23(35):8968-77. Ribas A, Camacho LH, Lopez-Berestein G, Pavlov D, Bulanhagui CA, Millham R, Comin-Anduix B, Reuben JM, Seja E, Parker CA, Sharma A, Glaspy JA, Gomez-Navarro J. PMID: 16204013.
      View in: PubMed   Mentions: 178     Fields:    Translation:HumansCellsCTClinical Trials
    111. Final results of a placebo-controlled study of filgrastim in small-cell lung cancer: exploration of risk factors for febrile neutropenia. Support Cancer Ther. 2005 Oct 01; 3(1):36-46. Crawford J, Glaspy JA, Stoller RG, Tomita DK, Vincent ME, McGuire BW, Ozer H. PMID: 18632435.
      View in: PubMed   Mentions: 17  
    112. Every-three-week erythropoietic support during chemotherapy for cancer: current status and future issues. Support Cancer Ther. 2005 Oct 01; 3(1):16-20. Glaspy JA. PMID: 18632430.
      View in: PubMed   Mentions: 1  
    113. Broad antitumor protection by dendritic cells administered to CD8alpha knock out mice. Cancer Immunol Immunother. 2006 Jun; 55(6):663-71. Ribas A, Vo DD, Weeks DL, Comin-Anduix B, Schumacher LY, Garban HJ, McLean C, Yang J, Dissette VB, Peraza P, Owens SK, McBride WH, Glaspy JA, Economou JS. PMID: 16133107.
      View in: PubMed   Mentions: 1     Fields:    Translation:AnimalsCells
    114. The development of erythropoietic agents in oncology. Expert Opin Emerg Drugs. 2005 Aug; 10(3):553-67. Glaspy JA. PMID: 16083329.
      View in: PubMed   Mentions:    Fields:    Translation:HumansAnimals
    115. Natural killer cells play a critical role in the immune response following immunization with melanoma-antigen-engineered dendritic cells. Cancer Gene Ther. 2005 Jun; 12(6):516-27. Wargo JA, Schumacher LY, Comin-Anduix B, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS, Ribas A. PMID: 15775996.
      View in: PubMed   Mentions: 10     Fields:    Translation:AnimalsCells
    116. Effects of chemotherapy on endogenous erythropoietin levels and the pharmacokinetics and erythropoietic response of darbepoetin alfa: a randomised clinical trial of synchronous versus asynchronous dosing of darbepoetin alfa. Eur J Cancer. 2005 May; 41(8):1140-9. Glaspy J, Henry D, Patel R, Tchekmedyian S, Applebaum S, Berdeaux D, Lloyd R, Berg R, Austin M, Rossi G, Darbepoetin Alfa 20010162 Study Group. PMID: 15911237.
      View in: PubMed   Mentions: 21     Fields:    Translation:HumansCTClinical Trials
    117. Entering a new era in the management of tumor-associated involution. J Support Oncol. 2005 Jan-Feb; 3(1):51-2. Glaspy JA. PMID: 15724945.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    118. Reductions in anaemia and fatigue are associated with improvements in productivity in cancer patients receiving chemotherapy. Pharmacoeconomics. 2005; 23(5):505-14. Berndt E, Kallich J, McDermott A, Xu X, Lee H, Glaspy J. PMID: 15896101.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    119. Anaemia management strategies: optimising treatment using epoetin beta (NeoRecormon). Oncology. 2005; 69 Suppl 2:8-16. Glaspy J, Beguin Y. PMID: 16244505.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    120. Novel interactions of vitamin E and estrogen in breast cancer. Nutr Cancer. 2005; 52(1):43-8. Chamras H, Barsky SH, Ardashian A, Navasartian D, Heber D, Glaspy JA. PMID: 16091003.
      View in: PubMed   Mentions: 11     Fields:    Translation:HumansCells
    121. Phase III clinical trials with darbepoetin: implications for clinicians. Best Pract Res Clin Haematol. 2005; 18(3):407-16. Glaspy J. PMID: 15792914.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    122. Role of dendritic cell phenotype, determinant spreading, and negative costimulatory blockade in dendritic cell-based melanoma immunotherapy. J Immunother. 2004 Sep-Oct; 27(5):354-67. Ribas A, Glaspy JA, Lee Y, Dissette VB, Seja E, Vu HT, Tchekmedyian NS, Oseguera D, Comin-Anduix B, Wargo JA, Amarnani SN, McBride WH, Economou JS, Butterfield LH. PMID: 15314544.
      View in: PubMed   Mentions: 37     Fields:    Translation:HumansCellsCTClinical Trials
    123. Surveillance of the eye and vision in a clinical trial of MART1-transformed dendritic cells for metastatic melanoma. Control Clin Trials. 2004 Aug; 25(4):400-7. Gordon LK, Ribas A, Nusinowitz S, Butterfield LH, Glaspy JA, Economou JS, Straatsma BR. PMID: 15296814.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCellsPHPublic Health
    124. Enhanced tumor responses to dendritic cells in the absence of CD8-positive cells. J Immunol. 2004 Apr 15; 172(8):4762-9. Ribas A, Wargo JA, Comin-Anduix B, Sanetti S, Schumacher LY, McLean C, Dissette VB, Glaspy JA, McBride WH, Butterfield LH, Economou JS. PMID: 15067052.
      View in: PubMed   Mentions: 9     Fields:    Translation:HumansAnimalsCells
    125. Can erythropoietin therapy improve survival? Oncology. 2004; 67 Suppl 1:5-11. Glaspy J, Dunst J. PMID: 15486447.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    126. Hematopoietic management in oncology practice. Part 2. Erythropoietic factors. Oncology (Williston Park). 2003 Dec; 17(12):1724-30; discussion 1731-2, 1735, 1739. Glaspy JA. PMID: 14723012.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    127. T-cell responses to HLA-A*0201 immunodominant peptides derived from alpha-fetoprotein in patients with hepatocellular cancer. Clin Cancer Res. 2003 Dec 01; 9(16 Pt 1):5902-8. Butterfield LH, Ribas A, Meng WS, Dissette VB, Amarnani S, Vu HT, Seja E, Todd K, Glaspy JA, McBride WH, Economou JS. PMID: 14676113.
      View in: PubMed   Mentions: 68     Fields:    Translation:HumansCellsCTClinical Trials
    128. Hematopoietic management in oncology practice. Part 1. Myeloid growth factors. Oncology (Williston Park). 2003 Nov; 17(11):1593-603. Glaspy JA. PMID: 14682110.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    129. Hemoglobin increase is associated with improved health-related quality of life in patients with cancer not receiving chemotherapy. Support Cancer Ther. 2003 Oct 01; 1(1):49-54. Smith JR, Glaspy JA, Tchekmedyian NS, Austin MD, Kallich JD. PMID: 18628131.
      View in: PubMed   Mentions: 3  
    130. Current developments in cancer vaccines and cellular immunotherapy. J Clin Oncol. 2003 Jun 15; 21(12):2415-32. Ribas A, Butterfield LH, Glaspy JA, Economou JS. PMID: 12805342.
      View in: PubMed   Mentions: 64     Fields:    Translation:HumansAnimals
    131. Treatment with histamine dihydrochloride and interleukin-2 in patients with advanced metastatic malignant melanoma: a detailed safety analysis. Melanoma Res. 2003 Jun; 13(3):307-11. O'Day SJ, Agarwala SS, Naredi P, Kass CL, Gehlsen KR, Glaspy J. PMID: 12777988.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCTClinical Trials
    132. The effect of anemia treatment on selected health-related quality-of-life domains: a systematic review. Clin Ther. 2003 Jun; 25(6):1786-805. Ross SD, Fahrbach K, Frame D, Scheye R, Connelly JE, Glaspy J. PMID: 12860499.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    133. A combined analysis of two pivotal randomized trials of a single dose of pegfilgrastim per chemotherapy cycle and daily Filgrastim in patients with stage II-IV breast cancer. Oncol Rep. 2003 May-Jun; 10(3):715-24. Siena S, Piccart MJ, Holmes FA, Glaspy J, Hackett J, Renwick JJ. PMID: 12684649.
      View in: PubMed   Mentions: 20     Fields:    Translation:HumansCTClinical Trials
    134. Multicenter phase II study of oral bexarotene for patients with metastatic breast cancer. J Clin Oncol. 2003 Mar 15; 21(6):999-1006. Esteva FJ, Glaspy J, Baidas S, Laufman L, Hutchins L, Dickler M, Tripathy D, Cohen R, DeMichele A, Yocum RC, Osborne CK, Hayes DF, Hortobagyi GN, Winer E, Demetri GD. PMID: 12637463.
      View in: PubMed   Mentions: 46     Fields:    Translation:HumansCTClinical Trials
    135. A randomized, active-control, pilot trial of front-loaded dosing regimens of darbepoetin-alfa for the treatment of patients with anemia during chemotherapy for malignant disease. Cancer. 2003 Mar 01; 97(5):1312-20. Glaspy JA, Jadeja JS, Justice G, Fleishman A, Rossi G, Colowick AB. PMID: 12599240.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansCTClinical Trials
    136. Determinant spreading associated with clinical response in dendritic cell-based immunotherapy for malignant melanoma. Clin Cancer Res. 2003 Mar; 9(3):998-1008. Butterfield LH, Ribas A, Dissette VB, Amarnani SN, Vu HT, Oseguera D, Wang HJ, Elashoff RM, McBride WH, Mukherji B, Cochran AJ, Glaspy JA, Economou JS. PMID: 12631598.
      View in: PubMed   Mentions: 89     Fields:    Translation:HumansCellsCTClinical Trials
    137. Differential effects of prostaglandin derived from omega-6 and omega-3 polyunsaturated fatty acids on COX-2 expression and IL-6 secretion. Proc Natl Acad Sci U S A. 2003 Feb 18; 100(4):1751-6. Bagga D, Wang L, Farias-Eisner R, Glaspy JA, Reddy ST. PMID: 12578976; PMCID: PMC149905.
      View in: PubMed   Mentions: 199     Fields:    Translation:AnimalsCells
    138. Bone pain associated with once-per-cycle pegfilgrastim is similar to daily filgrastim in patients with breast cancer. Clin Breast Cancer. 2003 Feb; 3(6):391-8. Kubista E, Glaspy J, Holmes FA, Green MD, Hackett J, Neumann T, Pegfilgrastim Study Group. PMID: 12636878.
      View in: PubMed   Mentions: 17     Fields:    Translation:Humans
    139. The health-related quality-of-life impact of histamine dihydrochloride plus interleukin-2 compared with interleukin-2 alone in patients with metastatic melanoma. Support Care Cancer. 2003 May; 11(5):304-12. Beusterien KM, Ackerman SJ, Plante K, Glaspy J, Naredi P, Wood D, Gehlsen K, Agarwala SS. PMID: 12720074.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    140. Fatty acid modulation of MCF-7 human breast cancer cell proliferation, apoptosis and differentiation. J Nutr Biochem. 2002 Dec; 13(12):711-716. Chamras H, Ardashian A, Heber D, Glaspy JA. PMID: 12550055.
      View in: PubMed   Mentions: 46     Fields:    
    141. Immunosuppressive effects of interleukin-12 coexpression in melanoma antigen gene-modified dendritic cell vaccines. Cancer Gene Ther. 2002 Nov; 9(11):875-83. Ribas A, Amarnani SN, Buga GM, Butterfield LH, Dissette VB, McBride WH, Glaspy JA, Ignarro LJ, Economou JS. PMID: 12386826.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansAnimalsCells
    142. Comparison of the isoelectric focusing patterns of darbepoetin alfa, recombinant human erythropoietin, and endogenous erythropoietin from human urine. Clin Chem. 2002 Nov; 48(11):2057-9. Catlin DH, Breidbach A, Elliott S, Glaspy J. PMID: 12406997.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    143. Darbepoetin alfa administered every 2 weeks alleviates anemia in cancer patients receiving chemotherapy. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):23-9. Glaspy JA, Tchekmedyian NS. PMID: 12435170.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    144. Darbepoetin alfa: impact on treatment for chemotherapy-induced anemia and considerations in special populations. Oncology (Williston Park). 2002 Oct; 16(10 Suppl 11):45-55. Vansteenkiste J, Poulsen E, Rossi G, Glaspy J. PMID: 12435173.
      View in: PubMed   Mentions: 5     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    145. The potential for anemia treatment to improve survival in cancer patients. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):35-40. Glaspy JA. PMID: 12380953.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    146. Overcoming barriers to erythropoietic therapy. Characteristics of darbepoetin alfa and potential advances in scheduling, dosing, and dose-efficiency. Oncology (Williston Park). 2002 Sep; 16(9 Suppl 10):71-7. Glaspy JA. PMID: 12380957.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    147. Relationship between changes in hemoglobin level and quality of life during chemotherapy in anemic cancer patients receiving epoetin alfa therapy. Cancer. 2002 Aug 15; 95(4):888-95. Crawford J, Cella D, Cleeland CS, Cremieux PY, Demetri GD, Sarokhan BJ, Slavin MB, Glaspy JA. PMID: 12209734.
      View in: PubMed   Mentions: 75     Fields:    Translation:HumansCTClinical Trials
    148. Use of complementary/alternative therapies by women with advanced-stage breast cancer. BMC Complement Altern Med. 2002 Aug 13; 2:8. Shen J, Andersen R, Albert PS, Wenger N, Glaspy J, Cole M, Shekelle P. PMID: 12175424; PMCID: PMC122074.
      View in: PubMed   Mentions: 50     Fields:    Translation:Humans
    149. Interferon-alpha induces dendritic cell differentiation of CML mononuclear cells in vitro and in vivo. Leukemia. 2002 Aug; 16(8):1484-9. Paquette RL, Hsu N, Said J, Mohammed M, Rao NP, Shih G, Schiller G, Sawyers C, Glaspy JA. PMID: 12145689.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansCells
    150. Standards of care for anemia management in oncology: focus on lung carcinoma. Cancer. 2002 Aug 01; 95(3):613-23. Langer CJ, Choy H, Glaspy JA, Colowick A. PMID: 12209755.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    151. Darbepoetin alfa given every 1 or 2 weeks alleviates anaemia associated with cancer chemotherapy. Br J Cancer. 2002 Jul 29; 87(3):268-76. Glaspy JA, Jadeja JS, Justice G, Kessler J, Richards D, Schwartzberg L, Tchekmedyian NS, Armstrong S, O'Byrne J, Rossi G, Colowick AB. PMID: 12177793; PMCID: PMC2364226.
      View in: PubMed   Mentions: 28     Fields:    Translation:HumansCTClinical Trials
    152. Pharmacokinetics of histamine dihydrochloride in healthy volunteers and cancer patients: implications for combined immunotherapy with interleukin-2. J Clin Pharmacol. 2002 Jul; 42(7):774-81. Middleton M, Sarno M, Agarwala SS, Glaspy J, Laurent A, McMasters K, Naredi P, O'Day S, Whitman E, Danson S, Cosford R, Gehlsen K. PMID: 12092744.
      View in: PubMed   Mentions: 6     Fields:    Translation:HumansCTClinical Trials
    153. Therapeutic options in the management of renal cell carcinoma. Semin Oncol. 2002 Jun; 29(3 Suppl 7):41-6. Glaspy JA. PMID: 12068388.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    154. Benefits of epoetin alfa in anemic breast cancer patients receiving chemotherapy. Clin Breast Cancer. 2002 Apr; 3(1):45-51. Demetri GD, Gabrilove JL, Blasi MV, Hill RJ, Glaspy J. PMID: 12020395.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    155. Culture conditions affect the ability of ex vivo expanded peripheral blood progenitor cells to accelerate hematopoietic recovery. Exp Hematol. 2002 Apr; 30(4):374-80. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. PMID: 11937274.
      View in: PubMed   Mentions: 4     Fields:    Translation:HumansCellsCTClinical Trials
    156. Cancer immunotherapy using gene-modified dendritic cells. Curr Gene Ther. 2002 Feb; 2(1):57-78. Ribas A, Butterfield LH, Glaspy JA, Economou JS. PMID: 12108974.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    157. Clinical benefits of epoetin alfa therapy in patients with lung cancer. Clin Lung Cancer. 2002 Feb; 3(3):180-90. Crawford J, Demetri GD, Gabrilove JL, Blasi MV, Sarokhan BJ, Glaspy J. PMID: 14662041.
      View in: PubMed   Mentions: 2     Fields:    
    158. Results from a randomized phase III study comparing combined treatment with histamine dihydrochloride plus interleukin-2 versus interleukin-2 alone in patients with metastatic melanoma. J Clin Oncol. 2002 Jan 01; 20(1):125-33. Agarwala SS, Glaspy J, O'Day SJ, Mitchell M, Gutheil J, Whitman E, Gonzalez R, Hersh E, Feun L, Belt R, Meyskens F, Hellstrand K, Wood D, Kirkwood JM, Gehlsen KR, Naredi P. PMID: 11773161.
      View in: PubMed   Mentions: 31     Fields:    Translation:HumansPHPublic HealthCTClinical Trials
    159. Long-chain n-3-to-n-6 polyunsaturated fatty acid ratios in breast adipose tissue from women with and without breast cancer. Nutr Cancer. 2002; 42(2):180-5. Bagga D, Anders KH, Wang HJ, Glaspy JA. PMID: 12416257.
      View in: PubMed   Mentions: 32     Fields:    Translation:Humans
    160. Comparable efficacy of epoetin alfa for anemic cancer patients receiving platinum- and nonplatinum-based chemotherapy: a retrospective subanalysis of two large, community-based trials. Oncologist. 2002; 7(2):126-35. Glaspy J, Degos L, Dicato M, Demetri GD. PMID: 11961196.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    161. alpha-Fetoprotein-specific tumor immunity induced by plasmid prime-adenovirus boost genetic vaccination. Cancer Res. 2001 Dec 15; 61(24):8782-6. Meng WS, Butterfield LH, Ribas A, Dissette VB, Heller JB, Miranda GA, Glaspy JA, McBride WH, Economou JS. PMID: 11751399.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansAnimalsCells
    162. CD40 cross-linking bypasses the absolute requirement for CD4 T cells during immunization with melanoma antigen gene-modified dendritic cells. Cancer Res. 2001 Dec 15; 61(24):8787-93. Ribas A, Butterfield LH, Amarnani SN, Dissette VB, Kim D, Meng WS, Miranda GA, Wang HJ, McBride WH, Glaspy JA, Economou JS. PMID: 11751400.
      View in: PubMed   Mentions: 12     Fields:    Translation:AnimalsCells
    163. T cell responses to HLA-A*0201-restricted peptides derived from human alpha fetoprotein. J Immunol. 2001 Apr 15; 166(8):5300-8. Butterfield LH, Meng WS, Koh A, Vollmer CM, Ribas A, Dissette VB, Faull K, Glaspy JA, McBride WH, Economou JS. PMID: 11290817.
      View in: PubMed   Mentions: 42     Fields:    Translation:HumansAnimalsCells
    164. Adenovirus-interleukin-12-mediated tumor regression in a murine hepatocellular carcinoma model is not dependent on CD1-restricted natural killer T cells. Cancer Res. 2000 Nov 15; 60(22):6457-64. Andrews KJ, Ribas A, Butterfield LH, Vollmer CM, Eilber FC, Dissette VB, Nelson SD, Shintaku P, Mekhoubad S, Nakayama T, Taniguchi M, Glaspy JA, McBride WH, Economou JS. PMID: 11103813.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCells
    165. Ex vivo expanded unselected peripheral blood: progenitor cells reduce posttransplantation neutropenia, thrombocytopenia, and anemia in patients with breast cancer. Blood. 2000 Oct 01; 96(7):2385-90. Paquette RL, Dergham ST, Karpf E, Wang HJ, Slamon DJ, Souza L, Glaspy JA. PMID: 11001888.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCells
    166. Hematologic supportive care of the critically ill cancer patient. Semin Oncol. 2000 Jun; 27(3):375-83. Glaspy JA. PMID: 10864224.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    167. Organochlorine pesticide content of breast adipose tissue from women with breast cancer and control subjects. J Natl Cancer Inst. 2000 May 03; 92(9):750-3. Bagga D, Anders KH, Wang HJ, Roberts E, Glaspy JA. PMID: 10793112.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    168. Immune deviation and Fas-mediated deletion limit antitumor activity after multiple dendritic cell vaccinations in mice. Cancer Res. 2000 Apr 15; 60(8):2218-24. Ribas A, Butterfield LH, Hu B, Dissette VB, Meng WS, Koh A, Andrews KJ, Lee M, Amar SN, Glaspy JA, McBride WH, Economou JS. PMID: 10786687.
      View in: PubMed   Mentions: 6     Fields:    Translation:AnimalsCellsPHPublic Health
    169. Generation of T-cell immunity to a murine melanoma using MART-1-engineered dendritic cells. J Immunother. 2000 Jan; 23(1):59-66. Ribas A, Butterfield LH, Hu B, Dissette VB, Chen AY, Koh A, Amarnani SN, Glaspy JA, McBride WH, Economou JS. PMID: 10687138.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    170. Characterization of antitumor immunization to a defined melanoma antigen using genetically engineered murine dendritic cells. Cancer Gene Ther. 1999 Nov-Dec; 6(6):523-36. Ribas A, Butterfield LH, McBride WH, Dissette VB, Koh A, Vollmer CM, Hu B, Chen AY, Glaspy JA, Economou JS. PMID: 10608349.
      View in: PubMed   Mentions: 8     Fields:    Translation:AnimalsCells
    171. p53 selective and nonselective replication of an E1B-deleted adenovirus in hepatocellular carcinoma. Cancer Res. 1999 Sep 01; 59(17):4369-74. Vollmer CM, Ribas A, Butterfield LH, Dissette VB, Andrews KJ, Eilber FC, Montejo LD, Chen AY, Hu B, Glaspy JA, McBride WH, Economou JS. PMID: 10485485.
      View in: PubMed   Mentions: 16     Fields:    Translation:HumansAnimalsCells
    172. Alpha-fetoprotein-specific genetic immunotherapy for hepatocellular carcinoma. Cancer Res. 1999 Jul 01; 59(13):3064-7. Vollmer CM, Eilber FC, Butterfield LH, Ribas A, Dissette VB, Koh A, Montejo LD, Lee MC, Andrews KJ, McBride WH, Glaspy JA, Economou JS. PMID: 10397245.
      View in: PubMed   Mentions: 36     Fields:    Translation:HumansAnimalsCells
    173. Generation of human T-cell responses to an HLA-A2.1-restricted peptide epitope derived from alpha-fetoprotein. Cancer Res. 1999 Jul 01; 59(13):3134-42. Butterfield LH, Koh A, Meng W, Vollmer CM, Ribas A, Dissette V, Lee E, Glaspy JA, McBride WH, Economou JS. PMID: 10397256.
      View in: PubMed   Mentions: 41     Fields:    Translation:HumansAnimalsCells
    174. Economic considerations in the use of peripheral blood progenitor cells to support high-dose chemotherapy. Bone Marrow Transplant. 1999 May; 23 Suppl 2:S21-7. Glaspy JA. PMID: 10335873.
      View in: PubMed   Mentions: 3     Fields:    Translation:Humans
    175. A randomized phase 3 study of peripheral blood progenitor cell mobilization with stem cell factor and filgrastim in high-risk breast cancer patients. Blood. 1999 Apr 15; 93(8):2491-501. Shpall EJ, Wheeler CA, Turner SA, Yanovich S, Brown RA, Pecora AL, Shea TC, Mangan KF, Williams SF, LeMaistre CF, Long GD, Jones R, Davis MW, Murphy-Filkins R, Parker WR, Glaspy JA. PMID: 10194427.
      View in: PubMed   Mentions: 10     Fields:    Translation:HumansCellsCTClinical Trials
    176. Antitumor protection using murine dendritic cells pulsed with acid-eluted peptides from in vivo grown tumors of different immunogenicities. Anticancer Res. 1999 Mar-Apr; 19(2A):1165-70. Ribas A, Bui LA, Butterfield LH, Vollmer CM, Jilani SM, Dissette VB, Glaspy JA, McBride WH, Economou JS. PMID: 10368670.
      View in: PubMed   Mentions: 3     Fields:    Translation:AnimalsCellsPHPublic Health
    177. Generation of melanoma-specific cytotoxic T lymphocytes by dendritic cells transduced with a MART-1 adenovirus. J Immunol. 1998 Nov 15; 161(10):5607-13. Butterfield LH, Jilani SM, Chakraborty NG, Bui LA, Ribas A, Dissette VB, Lau R, Gamradt SC, Glaspy JA, McBride WH, Mukherji B, Economou JS. PMID: 9820539.
      View in: PubMed   Mentions: 26     Fields:    Translation:HumansCells
    178. Impact of epoetin alfa in chemotherapy-associated anemia. Semin Oncol. 1998 Oct; 25(5):571-6. Jilani SM, Glaspy JA. PMID: 9783596.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    179. Interferon-alpha and granulocyte-macrophage colony-stimulating factor differentiate peripheral blood monocytes into potent antigen-presenting cells. J Leukoc Biol. 1998 Sep; 64(3):358-67. Paquette RL, Hsu NC, Kiertscher SM, Park AN, Tran L, Roth MD, Glaspy JA. PMID: 9738663.
      View in: PubMed   Mentions: 71     Fields:    Translation:HumansCells
    180. Phase II study of receptor-enhanced chemosensitivity using recombinant humanized anti-p185HER2/neu monoclonal antibody plus cisplatin in patients with HER2/neu-overexpressing metastatic breast cancer refractory to chemotherapy treatment. J Clin Oncol. 1998 Aug; 16(8):2659-71. Pegram MD, Lipton A, Hayes DF, Weber BL, Baselga JM, Tripathy D, Baly D, Baughman SA, Twaddell T, Glaspy JA, Slamon DJ. PMID: 9704716.
      View in: PubMed   Mentions: 207     Fields:    Translation:HumansCTClinical Trials
    181. Accuracy of whole-body fluorine-18-FDG PET for the detection of recurrent or metastatic breast carcinoma. J Nucl Med. 1998 Mar; 39(3):431-5. Moon DH, Maddahi J, Silverman DH, Glaspy JA, Phelps ME, Hoh CK. PMID: 9529287.
      View in: PubMed   Mentions: 33     Fields:    Translation:Humans
    182. Empirical criteria for the selection of quality-of-life instruments for the evaluation of peripheral blood progenitor cell transplantation. Int J Technol Assess Health Care. 1998; 14(3):419-30. Glick HA, Shpall EJ, LeMaistre CF, McCarron TJ, Lu ZJ, Erder MH, Glaspy JA. PMID: 9780529.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    183. Effect of CD34+ peripheral blood progenitor cell dose on hematopoietic recovery. Biol Blood Marrow Transplant. 1998; 4(2):84-92. Shpall EJ, Champlin R, Glaspy JA. PMID: 9763111.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    184. In vivo therapy of hepatocellular carcinoma with a tumor-specific adenoviral vector expressing interleukin-2. Hum Gene Ther. 1997 Dec 10; 8(18):2173-82. Bui LA, Butterfield LH, Kim JY, Ribas A, Seu P, Lau R, Glaspy JA, McBride WH, Economou JS. PMID: 9449371.
      View in: PubMed   Mentions: 12     Fields:    Translation:HumansAnimalsCells
    185. Peripheral blood progenitor cell mobilization using stem cell factor in combination with filgrastim in breast cancer patients. Blood. 1997 Oct 15; 90(8):2939-51. Glaspy JA, Shpall EJ, LeMaistre CF, Briddell RA, Menchaca DM, Turner SA, Lill M, Chap L, Jones R, Wiers MD, Sheridan WP, McNiece IK. PMID: 9376574.
      View in: PubMed   Mentions: 15     Fields:    Translation:HumansCellsCTClinical Trials
    186. Relationship between omega-3 and omega-6 fatty acid ratios and breast cancer. Nutrition. 1997 Sep; 13(9):822-4. Capone SL, Bagga D, Glaspy JA. PMID: 9290101.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    187. Dietary modulation of omega-3/omega-6 polyunsaturated fatty acid ratios in patients with breast cancer. J Natl Cancer Inst. 1997 Aug 06; 89(15):1123-31. Bagga D, Capone S, Wang HJ, Heber D, Lill M, Chap L, Glaspy JA. PMID: 9262250.
      View in: PubMed   Mentions: 21     Fields:    Translation:Humans
    188. Genetic immunization for the melanoma antigen MART-1/Melan-A using recombinant adenovirus-transduced murine dendritic cells. Cancer Res. 1997 Jul 15; 57(14):2865-9. Ribas A, Butterfield LH, McBride WH, Jilani SM, Bui LA, Vollmer CM, Lau R, Dissette VB, Hu B, Chen AY, Glaspy JA, Economou JS. PMID: 9230191.
      View in: PubMed   Mentions: 29     Fields:    Translation:HumansAnimalsCellsPHPublic Health
    189. Megakaryocyte growth and development factor (MGDF) moderately enhances in-vitro platelet aggregation. Thromb Res. 1995 Oct 01; 80(1):23-33. Toombs CF, Young CH, Glaspy JA, Varnum BC. PMID: 8578535.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    190. Alterations in phenotype and cell-surface antigen expression levels of human monocytes: differential response to in vivo administration of rhM-CSF or rhGM-CSF. Cytometry. 1995 Jun 15; 22(2):103-10. Schmid I, Baldwin GC, Jacobs EL, Isacescu V, Neagos N, Giorgi JV, Glaspy JA. PMID: 7587740.
      View in: PubMed   Mentions: 14     Fields:    Translation:HumansCellsCTClinical Trials
    191. Quantitative PET imaging of bone marrow glucose metabolic response to hematopoietic cytokines. J Nucl Med. 1995 May; 36(5):794-9. Yao WJ, Hoh CK, Hawkins RA, Glaspy JA, Weil JA, Lee SJ, Maddahi J, Phelps ME. PMID: 7738650.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    192. Production of functional myeloid cells from CD34-selected hematopoietic progenitor cells using a clinically relevant ex vivo expansion system. Stem Cells. 1994 Nov; 12(6):626-37. Lill MC, Lynch M, Fraser JK, Chung GY, Schiller G, Glaspy JA, Souza L, Baldwin GC, Gasson JC. PMID: 7533581.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    193. The clinical application of recombinant erythropoietin in the HIV-infected patient. Hematol Oncol Clin North Am. 1994 Oct; 8(5):945-59. Glaspy JA, Chap L. PMID: 7852217.
      View in: PubMed   Mentions:    Fields:    Translation:Humans
    194. Cost considerations in therapy with myeloid growth factors. Am J Hosp Pharm. 1993 Jul; 50(7 Suppl 3):S19-26. Glaspy JA, Jakway J. PMID: 7689789.
      View in: PubMed   Mentions: 4     Fields:    Translation:Humans
    195. Use of positron emission tomography in oncology. Oncology (Williston Park). 1993 Jul; 7(7):41-6, 49-50; discussion 50-2, 55. Glaspy JA, Hawkins R, Hoh CK, Phelps ME. PMID: 8347460.
      View in: PubMed   Mentions: 9     Fields:    Translation:Humans
    196. Imaging of pulmonary mass lesions with whole-body positron emission tomography and fluorodeoxyglucose. Cancer. 1993 Jul 01; 72(1):82-90. Rege SD, Hoh CK, Glaspy JA, Aberle DR, Dahlbom M, Razavi MK, Phelps ME, Hawkins RA. PMID: 8389668.
      View in: PubMed   Mentions: 13     Fields:    Translation:Humans
    197. Adult-onset cyclic neutropenia responsive to cyclosporine therapy in a patient with ankylosing spondylitis. Am J Hematol. 1993 Jun; 43(2):139-43. Storek J, Glaspy JA, Grody WW, Susi E, Slater ED. PMID: 7688178.
      View in: PubMed   Mentions: 2     Fields:    Translation:Humans
    198. The impact of therapy with filgrastim (recombinant granulocyte colony-stimulating factor) on the health care costs associated with cancer chemotherapy. Eur J Cancer. 1993; 29A Suppl 7:S23-30. Glaspy JA, Bleecker G, Crawford J, Stoller R, Strauss M. PMID: 7508727.
      View in: PubMed   Mentions: 8     Fields:    Translation:HumansCTClinical Trials
    199. Hemostatic abnormalities in multiple myeloma and related disorders. Hematol Oncol Clin North Am. 1992 Dec; 6(6):1301-14. Glaspy JA. PMID: 1452513.
      View in: PubMed   Mentions: 6     Fields:    Translation:Humans
    200. Quantification of glucose utilization in liver metastases: parametric imaging of FDG uptake with PET. J Comput Assist Tomogr. 1992 Sep-Oct; 16(5):684-9. Messa C, Choi Y, Hoh CK, Jacobs EL, Glaspy JA, Rege S, Nitzsche E, Huang SC, Phelps ME, Hawkins RA. PMID: 1522257.
      View in: PubMed   Mentions: 24     Fields:    Translation:Humans
    201. Granulocyte colony-stimulating factor (G-CSF): preclinical and clinical studies. Semin Oncol. 1992 Aug; 19(4):386-94. Glaspy JA, Golde DW. PMID: 1380729.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansAnimalsCTClinical Trials
    202. Treatment of hairy cell leukemia with granulocyte colony-stimulating factor and recombinant consensus interferon or recombinant interferon-alpha-2b. J Immunother (1991). 1992 Apr; 11(3):198-208. Glaspy JA, Souza L, Scates S, Narachi M, Blatt L, Ambersley J, Golde DW. PMID: 1381218.
      View in: PubMed   Mentions: 2     Fields:    Translation:HumansCTClinical Trials
    203. The impact of granulocyte colony-stimulating factor on quality of life in patients with severe chronic neutropenia. Oncol Nurs Forum. 1991 Nov-Dec; 18(8):1411-4. Fazio MT, Glaspy JA. PMID: 1722310.
      View in: PubMed   Mentions: 7     Fields:    Translation:HumansCTClinical Trials
    204. Neutropenia in an extremely premature infant treated with recombinant human granulocyte colony-stimulating factor. Am J Dis Child. 1991 Jul; 145(7):808-12. Roberts RL, Szelc CM, Scates SM, Boyd MT, Soderstrom KM, Davis MW, Glaspy JA. PMID: 1711773.
      View in: PubMed   Mentions: 7     Fields:    Translation:Humans
    205. Combined therapy with recombinant granulocyte colony-stimulating factor and erythropoietin decreases hematologic toxicity from zidovudine. Blood. 1991 May 15; 77(10):2109-17. Miles SA, Mitsuyasu RT, Moreno J, Baldwin G, Alton NK, Souza L, Glaspy JA. PMID: 1709368.
      View in: PubMed   Mentions: 18     Fields:    Translation:HumansCells
    206. Clinical trials of myeloid growth factors. Exp Hematol. 1990 Nov; 18(10):1137-41. Glaspy JA, Golde DW. PMID: 1698650.
      View in: PubMed   Mentions: 1     Fields:    Translation:HumansCTClinical Trials
    207. The colony-stimulating factors: biology and clinical use. Oncology (Williston Park). 1990 Sep; 4(9):25-32; discussion 32-4. Glaspy JA, Golde DW. PMID: 2145019.
      View in: PubMed   Mentions: 1     Fields:    Translation:Humans
    208. Recombinant human granulocyte colony-stimulating factor increases circulating burst forming unit-erythron and red blood cell production in patients with severe human immunodeficiency virus infection. Blood. 1990 Jun 01; 75(11):2137-42. Miles SA, Mitsuyasu RT, Lee K, Moreno J, Alton K, Egrie JC, Souza L, Glaspy JA. PMID: 1693297.
      View in: PubMed   Mentions: 3     Fields:    Translation:HumansCells
    209. The promise of colony-stimulating factors in clinical practice. Oncol Nurs Forum. 1990 Jan-Feb; 17(1 Suppl):20-4. Glaspy JA, Ambersley JM. PMID: 1689043.
      View in: PubMed   Mentions:    Fields:    Translation:HumansCells
    210. Therapy for neutropenia in hairy cell leukemia with recombinant human granulocyte colony-stimulating factor. Ann Intern Med. 1988 Nov 15; 109(10):789-95. Glaspy JA, Baldwin GC, Robertson PA, Souza L, Vincent M, Ambersley J, Golde DW. PMID: 2461131.
      View in: PubMed   Mentions: 19     Fields:    Translation:HumansCells
    John's Networks
    Concepts (690)
    Derived automatically from this person's publications.
    _
    Co-Authors (80)
    People in Profiles who have published with this person.
    _
    Similar People (60)
    People who share similar concepts with this person.
    _
    Same Department
    Search Department
    _